# nature portfolio

Corresponding author(s): Takeharu Nagai

Last updated by author(s): October, 17, 2022

# **Reporting Summary**

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our Editorial Policies and the Editorial Policy Checklist.

#### Statistics

For	all st	atistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.
n/a	Cor	firmed
	$\mathbf{X}$	The exact sample size ( $n$ ) for each experimental group/condition, given as a discrete number and unit of measurement
	$\mathbf{X}$	A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
$\times$		The statistical test(s) used AND whether they are one- or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.
$\times$		A description of all covariates tested
$\times$		A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
$\times$		A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
$\times$		For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i> ) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted Give <i>P</i> values as exact values whenever suitable.
$\times$		For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
$\times$		For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
$\times$		Estimates of effect sizes (e.g. Cohen's d, Pearson's r), indicating how they were calculated
		Our web collection on <u>statistics for biologists</u> contains articles on many of the points above.

### Software and code

Policy information about <u>availability of computer code</u>						
Data collection	Imaging data were collected using Fusion v.2.3.0.45 (Andor). Spectra data were collected using FL solution (Hitachi).					
Data analysis	Image data were processed in Fiji software (SciJava). Data analysis were performed using Ngraph v.6.53.03 (Satoshi Ishizaka) and Microsoft Excel 2016.					

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio guidelines for submitting code & software for further information.

### Data

Policy information about availability of data

All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our policy

Data supporting the results of this study can be found in the article and its appendices. All other data and materials supporting the results of this study are available from the corresponding author upon reasonable request.

# nature portfolio | reporting summary

## Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

🛛 Life sciences 🔹 Behavioural & social sciences 🔄 Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see <u>nature.com/documents/nr-reporting-summary-flat.pdf</u>

### Life sciences study design

All studies must disclose on these points even when the disclosure is negative.					
Sample size	In most cases, N = 3 independent experiments were performed, and exceptions are noted in figure legend.				
Data exclusions	No data were excluded.				
Replication	All results have been verified for reproducibility by independent experiments.				
Randomization	The cells observed in this study were randomly selected to express fluorescent proteins.				
Blinding	No experiments were performed that required blinding.				

# Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

Materials & experimental systems	Methods	
n/a Involved in the study	n/a Involved in the study	
X Antibodies	ChIP-seq	
Eukaryotic cell lines	Flow cytometry	
Palaeontology and archaeology	MRI-based neuroimaging	
Animals and other organisms		
🔀 🔲 Clinical data		
🗙 🔲 Dual use research of concern		

### Eukaryotic cell lines

Policy information about <u>cell lines and Sex and Gender in Research</u>						
Cell line source(s)	HeLa (S3) cells from RIKEN BRC were used.					
Authentication	Cell lines have not received additional authentication.					
Mycoplasma contamination	Celluline has not been tested for mycoplasma.					
Commonly misidentified lines (See <u>ICLAC</u> register)	Common misidentified cell lines are not used.					